Exploration of N6-methyladenosine modification in ascorbic acid 2-glucoside constructed stem cell sheets
Journal of Molecular Histology · 2024
DOI: 10.1007/s10735-024-10240-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Histology, 2024. Verfasst von Zhiye Yao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatal Intensive Care Unit, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical Universi…. Hauptthemen laut MEDLINE: Ascorbic Acid, Adenosine. Die Arbeit nennt 52 Literaturangaben.
Abstract (Originalsprache)
The aim of this study was to explore the mechanism of bone marrow stem cells (BMSCs) sheets constructed with different doses of Ascorbic acid 2-glucoside (AA-2G) in conjunction with N6-methyladenosine (m6A)-associated epigenetic genes analysing transcriptome sequencing data. Experimental groups of BMSCs induced by different AA-2G concentrations were set up, and the tissue structures were observed by histological staining of cell slices and scanning electron microscopy. Expression patterns of DEGs were analysed using short-time sequence expression mining software, and DEGs associated with m6A were selected for gene ontology analysis and pathway analysis. The protein-protein interaction (PPI) network of DEGs was analysed and gene functions were predicted using the search tool of the Retrieve Interacting Genes database. There were 464 up-regulated DEGs and 303 down-regulated DEGs between the control and high-dose AA-2G treatment groups, and 175 up-regulated DEGs and 37 down-regulated DEGs between the low and high-dose AA-2G treatment groups. The profile 7 exhibited a gradual increase in gene expression levels over AA-2G concentration. In contrast, profile 0 exhibited a gradual decrease in gene expression levels over AA-2G concentration. In the PPI network of m6A-related DEGs in profile 7, the cluster of metallopeptidase inhibitor 1 (Timp1), intercellular adhesion molecule 1 (Icam1), insulin-like growth factor 1 (Igf1), matrix metallopeptidase 2 (Mmp2), serpin family E member 1 (Serpine1), C-X-C motif chemokine ligand 2 (Cxcl2), galectin 3 (Lgals3) and angiopoietin-1 (Angpt1) was the top hub gene cluster. The expression of all hub genes was significantly increased after AA-2G intervention (P < 0.05), and the expression of Igf1 and Timp1 increased with increasing intervention concentration. The m6A epigenetic modifications were involved in the AA-2G-induced formation of BMSCs. Igf1, Serpine1 and Cxcl2 in DEGs were enriched for tissue repair, promotion of endothelial and epithelial proliferation and regulation of apoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neonatal Intensive Care Unit, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106 of Zhongshan Er Road, Yuexiu District, Guangzhou, 510080,…
- Department of Child Health Care, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
- Department of Neonatology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Zitieren
APA
Yao, Z., Chen, L., Liu, Y., Feng, B., Liu, C., Chen, Y., & He, S. (2024). Exploration of N6-methyladenosine modification in ascorbic acid 2-glucoside constructed stem cell sheets. Journal of Molecular Histology. https://doi.org/10.1007/s10735-024-10240-2
Vancouver
Yao Z, Chen L, Liu Y, Feng B, Liu C, Chen Y, et al. Exploration of N6-methyladenosine modification in ascorbic acid 2-glucoside constructed stem cell sheets. Journal of Molecular Histology. 2024. doi:10.1007/s10735-024-10240-2
BibTeX
@article{Yao2024,
author = {Yao, Zhiye and Chen, Liang and Liu, Yumei and Feng, Bowen and Liu, Caisheng and Chen, Yanling and He, Shaoru},
title = {Exploration of N6-methyladenosine modification in ascorbic acid 2-glucoside constructed stem cell sheets},
journal = {Journal of Molecular Histology},
year = {2024},
doi = {10.1007/s10735-024-10240-2}
}
EUVIMED